ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1452

Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis

James Sullivan1 and Emily Littlejohn2, 1Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH

Meeting: ACR Convergence 2022

Keywords: glucocorticoids, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards better understanding the mechanisms by which patients remain on long-term glucocorticoids despite the availability of steroid sparing therapies. We sought to characterize the healthcare use of patients with SLE on long-term moderate to high dose glucocorticoid therapy.

Methods: We utilized an SLE registry at a large academic institution to compare acute care and outpatient resource utilization over one year among participants on long-term, moderate to high dose glucocorticoids. SLE was defined by either SLICC or ACR/EULAR criteria. Variables collected in the registry include, but are not limited to, age, sex, race, income, SLE medications, hospitalizations due to SLE, and SLE disease activity index 2000 (SLEDAI-2K). In the year prior to a participant’s first recorded SLEDAI-2K, we reviewed the medical record for emergency department visits and outpatient visits stratified by specialty and inclusion of ≥1 SLE-related diagnosis code. Long-term glucocorticoid use and typical dose were adjudicated in the medical record. Tapers and intravenous glucocorticoids were not considered long-term use. We defined high acute care utilization as ≥2 emergency department visits in the past year and moderate to high dose glucocorticoid use as a daily oral dose of >10 mg. Multivariable logistic regression of glucocorticoid use and high acute care use was performed, adjusting for SLEDAI-2K, hospitalization related to SLE, ≤3 SLE-related outpatient visits, and annual income < $25,000.

Results: Table 1 lists characteristics of the final 203 participant sample. A total of 100 participants were on long-term glucocorticoids, 55 of which were on 1-10 mg daily and 45 were on >10 mg daily. Among those not on glucocorticoids, 15% had ≥2 emergency department visits while 19% and 47% of those taking 1-10mg and >10mg daily had ≥2 emergency department visits, respectively. Medication, outpatient visits, and acute care use are listed in Table 2. In unadjusted analyses, moderate to high dose glucocorticoid use was associated with ≥2 emergency department visits in the past year (OR 4.4; 95%CI 2.2-9.1) and SLEDAI-2K ≥6 (OR 12.7; 95%CI 5.8-27.8), but not >2 rheumatologist visits or ≤3 SLE-related outpatient visits in the past year. The multivariable logistic regression model results are listed in Table 3. After adjusting for covariates, participants with high acute care utilization were more than 8-fold more likely to use long-term moderate to high dose glucocorticoids (adjusted OR 8.6; 95% CI 3.0-24.7; p< 0.0001, Table 2).

Conclusion: After adjusting for disease activity, annual income, hospitalization in the past year, and SLE-related outpatient visits, patients with SLE and high acute care use were more likely to use long-term moderate to high dose glucocorticoids. The reason for this association is likely multifactorial and warrants further exploration. Future research should examine the precise causes of this finding and future intervention should aim to increase the use of steroid sparing medications in this population.

Supporting image 1

Table 1. Cohort characteristics of the SLE registry

Supporting image 2

Table 2. Medication, outpatient visits, and acute care use among SLE registry participants

Supporting image 3

Table 3. Multivariable logistic regression of odds of long-term moderate to high dose (>10 mg daily) oral glucocorticoid use among participants in the SLE registry


Disclosures: J. Sullivan, None; E. Littlejohn, Aurinia.

To cite this abstract in AMA style:

Sullivan J, Littlejohn E. Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/patterns-of-outpatient-and-acute-care-use-among-patients-with-sle-on-long-term-moderate-to-high-dose-glucocorticoid-medication-a-1-year-retrospective-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-outpatient-and-acute-care-use-among-patients-with-sle-on-long-term-moderate-to-high-dose-glucocorticoid-medication-a-1-year-retrospective-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology